TISSEEL KIT VH 2.0 100 UNIT / 2 ML — DIN 02233274
FACTOR XIII : 100 UNIT / 2 ML CALCIUM CHLORIDE : 80 MCMOL / 2 ML TOTAL PROTEIN : 260 MG / 2 ML PLASMAFIBRONECTIN (CIG) : 18 MG / 2 ML PLASMINOGEN : 240 MCG / 2 ML THROMBIN (HUMAN) : 8 UNIT / 2 ML FIBRINOGEN (HUMAN) : 220 MG / 2 ML THROMBIN (HUMAN) : 1000 UNIT / 2 ML APROTININ (BOVINE) : 6000 KIU / 2 ML · BAXTER AG · KIT ; POWDER FOR SOLUTION ; LIQUID · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is TISSEEL KIT VH 2.0?
TISSEEL KIT VH 2.0 100 UNIT / 2 ML contains FACTOR XIII : 100 UNIT / 2 ML CALCIUM CHLORIDE : 80 MCMOL / 2 ML TOTAL PROTEIN : 260 MG / 2 ML PLASMAFIBRONECTIN (CIG) : 18 MG / 2 ML PLASMINOGEN : 240 MCG / 2 ML THROMBIN (HUMAN) : 8 UNIT / 2 ML FIBRINOGEN (HUMAN) : 220 MG / 2 ML THROMBIN (HUMAN) : 1000 UNIT / 2 ML APROTININ (BOVINE) : 6000 KIU / 2 ML. It is listed in the Health Canada Drug Product Database under DIN 02233274, held by BAXTER AG, supplied as KIT ; POWDER FOR SOLUTION ; LIQUID for TOPICAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Jun-2014. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is TISSEEL KIT VH 2.0 used for?
Used in addition to standard measures to achieve hemostasis, seal or glue tissue, and support wound healing in abdominal, cardiovascular, orthopedic, thoracic surgery, and urology.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Combinations cost around the world?
Combinations is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Hungary publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 5 | 5 | HUF███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
8 pack listings across 8 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Combinations pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Combinations, across 8 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. | 3 | 0 | TISSEEL KIT VH, TISSEEL KIT VH 0.5, TISSEEL KIT VH 2.0 | No marketed DIN |
| BAXTER AG Industriestrasse 67 Vienna Saone Et Loire Austria 1220 | 2 | 0 | TISSEEL KIT VH 1.0, TISSEEL KIT VH 5.0 | No marketed DIN |
| OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. 67 Industriestrasse Vienna -- Austria 1221 | 2 | 0 | TISSEEL KIT VH 1.0, TISSEEL KIT VH 5.0 | No marketed DIN |
| BAXTER AG | 1 | 0 | TISSEEL KIT VH 2.0 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 UNIT / 2 ML |
|---|---|
| Dosage form | KIT ; POWDER FOR SOLUTION ; LIQUID |
| Route | TOPICAL |
| Pack configuration (monograph) | Kit containing five vials (Sealer Protein, Aprotinin, Thrombin 4, Thrombin 500, Calcium Chloride) and an application set (Duploject, syringes, joining pieces, needles). |
| Storage | Not explicitly detailed in provided text (standard practice is 2-8°C or 15-25°C depending on form, but text only mentions warming to 33-37°C before use). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Combinations |
|---|---|
| ATC code | B02BD20 |
| AHFS class | 20:28.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02233274 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2233274 |
| Brand name | TISSEEL KIT VH 2.0 |
| Generic / active ingredient | FACTOR XIII : 100 UNIT / 2 ML CALCIUM CHLORIDE : 80 MCMOL / 2 ML TOTAL PROTEIN : 260 MG / 2 ML PLASMAFIBRONECTIN (CIG) : 18 MG / 2 ML PLASMINOGEN : 240 MCG / 2 ML THROMBIN (HUMAN) : 8 UNIT / 2 ML FIBRINOGEN (HUMAN) : 220 MG / 2 ML THROMBIN (HUMAN) : 1000 UNIT / 2 ML APROTININ (BOVINE) : 6000 KIU / 2 ML |
| Market authorization holder | BAXTER AG |
| Health Canada schedule | Prescription |
| ATC code | B02BD20 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B02BD |
| Current status | CANCELLED POST MARKET |
| Status date | 10-Jun-2014 |
| Original market date | 1998-10-13 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Topical use only. Reconstitute freeze-dried components. Apply as a thin layer using Duploject system (needle, spray, or catheter). Dose depends on surface area (1.0 mL covers ~10-100 cm2).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Not for severe/brisk arterial or venous bleeding. Known hypersensitivity to bovine protein or any constituents, including aprotinin.
Warnings and precautions
Risk of viral transmission. Do not apply intravascularly (risk of thromboembolism). Risk of air/gas embolism with spray devices. Potential for fatal anaphylactic reactions.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TISSEEL KIT VH | 4 UNIT | JELLY | OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. | CANCELLED POST MARKET | 00677558 |
| TISSEEL KIT VH 0.5 | 3000 UNIT | POWDER FOR SOLUTION ; LIQUID | OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. | CANCELLED POST MARKET | 02017229 |
| TISSEEL KIT VH 1.0 | Strength | Powder For Solution , Kit , Liquid | BAXTER AG Industriestrasse 67 Vienna Saone Et Loire Austria 1220 | CANCELLED POST MARKET | 02233273 |
| TISSEEL KIT VH 1.0 | Strength | Powder For Solution , Liquid | OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. 67 Industriestrasse Vienna -- Austria 1221 | CANCELLED POST MARKET | 01949020 |
| TISSEEL KIT VH 2.0 | 9 MG | POWDER FOR SOLUTION | OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. | CANCELLED POST MARKET | 01949012 |
| TISSEEL KIT VH 5.0 | Strength | Powder For Solution | OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. 67 Industriestrasse Vienna -- Austria 1221 | CANCELLED POST MARKET | 01974327 |
| TISSEEL KIT VH 5.0 | Strength | Kit , Powder For Solution , Liquid | BAXTER AG Industriestrasse 67 Vienna Saone Et Loire Austria 1220 | CANCELLED POST MARKET | 02233275 |
2 · Same class — other molecules in ATC B02BD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Coagulation Factor Viii | ADVATE · ADYNOVATE · AFSTYLA · ALTUVIIIO · +34 more | 134 | 38 | Yes |
| Coagulation Factor Ix | ALPHANINE PWS INJ 1500UNIT/VIAL · ALPROLIX · BEBULIN VH 500UNIT/VIAL · BEBULIN VH INJ 1000UNIT/VIAL · +8 more | 33 | 16 | Yes |
| Von Willebrand Factor And Coag. Fact. Viii In Comb | ALPHANATE · HUMATE-P · WILATE | 10 | 5 | Yes |
| Coagulation Factor Ix, Ii, Vii And X In Comb | BERIPLEX P/N 1000 · BERIPLEX P/N 500 · OCTAPLEX | 4 | 4 | Yes |
| Coagulation Factor Viia | NIASTASE · NIASTASE RT | 11 | 3 | Yes |
| Factor Viii Inhibitor Bypassing Activity | FEIBA NF · FEIBA VH IMMUNO ANTI INHIBITOR | 5 | 2 | Yes |
| Coagulation Factor Xiii | CORIFACT 1250 · CORIFACT 250 | 2 | 2 | Yes |
| Thrombin | RECOTHROM · THROMBOGEN SPRAY KIT · VISTASEAL | 4 | 1 | Yes |
| Catridecacog | TRETTEN | 1 | 1 | Yes |
| Etranacogene Dezaparvovec | HEMGENIX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B02BX | Avatrombopag · Concizumab · Eltrombopag · Emicizumab · Fostamatinib · +1 more | 23 | 15 |
| B02BC | Combinations · Epinephrine · Local Hemostatics · Thrombin | 23 | 6 |
| B02BA | Phytomenadione | 5 | 2 |
| B02BB | Fibrinogen, Human | 2 | 2 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADYNOVATE | ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED : 1000 UNIT | TAKEDA CANADA INC | MARKETED | 02498588 |
| ALPROLIX | RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN : 500 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02422913 |
| ALTUVIIIO | *ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, BDD), FC-VWF-XTEN FUSION PROTEIN : 4000 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02448157 |
| ELOCTATE | ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN : 500 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02430304 |
| ESPEROCT | ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED : 2000 UNIT | NOVO NORDISK CANADA INC | MARKETED | 02490099 |
| JIVI | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) : 1000 UNIT | BAYER INC | MARKETED | 02481774 |
| REBINYN | COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED : 3000 UNIT | NOVO NORDISK CANADA INC | MARKETED | 02532964 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TISSEEL KIT VH 2.0 called?
The same molecule, Combinations, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ekyflogyl | Latin | Iceland |
| OTIPAX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.